Möchten Sie immer auf dem neuesten Stand bleiben?

AMSTERDAM, the Netherlands, April 4, 2016 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by uniQure N.V. (NASDAQ:QURE), the tables were not included. The corrected...

AMSTERDAM, the Netherlands, April 4, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced audited results for the fourth quarter and year ending...

AMSTERDAM, the Netherlands, March 22, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the publication of preclinical data supporting its...

AMSTERDAM, the Netherlands, March 14, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has treated the first patient in the second...

AMSTERDAM, the Netherlands, March 2, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, announced today that its management will present at the 36th Cowen &...

AMSTERDAM, the Netherlands, Feb. 15, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, announced today that Dan Soland, Chief Executive Officer, will present at...

--Meaningful Factor IX Expression Validates Successful Transduction of the Liver Using uniQure's Proprietary AAV5 Vector-- --Four of Five Patients Have Fully Discontinued Prophylactic Recombinant...

AMSTERDAM, the Netherlands, Jan. 6, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company will release topline results from its...

AMSTERDAM, the Netherlands, Dec. 18, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Dan Soland as the new Chief Executive...

AMSTERDAM, the Netherlands, Dec. 14, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has been added to the NASDAQ Biotechnology...